Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS

  • STATUS
    Not Recruiting
  • participants needed
    15
  • sponsor
    NeuroSense Therapeutics Ltd.
Updated on 29 January 2022
riluzole
edaravone

Summary

This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability and routine disease progression measures (ALSFRS-R and Vital Capacity).

Description

Patients will be prescribed a fixed dose combination of Ciprofloxacin and Celecoxib to be taken thrice daily, and will be monitored for safety and tolerability. Additionally, routine disease progression measures will be assessed.

Details
Condition Amyotrophic Lateral Sclerosis, Antilymphocyte Serum
Treatment Fixed dose combination Ciprofloxacin/Celecoxib
Clinical Study IdentifierNCT04165850
SponsorNeuroSense Therapeutics Ltd.
Last Modified on29 January 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note